Unichem Laboratories Limited Sets Q2 FY27 Results Meeting for Nov 4

Unichem Laboratories Limited will consider its unaudited Q2 FY27 financial results on November 4, 2026, for the quarter and six months ended September 30, 2026. The meeting follows a consolidated Q1 FY27 performance in which revenue reached ₹648 crore and net profit was ₹42 crore, compared with a loss a year earlier.

What will Unichem Laboratories consider at its November 4 board meeting?

Unichem Laboratories will consider and approve unaudited financial results for the second quarter and first six months of FY27 at its Board of Directors meeting scheduled for Wednesday, November 4, 2026. The company has informed both BSE Ltd. and the National Stock Exchange of India Ltd. about the meeting through its board-meeting notice.

The agenda covers the period ended September 30, 2026. The results are to be reviewed in both consolidated and standalone formats, which will allow investors to assess the performance of the company and its group entities separately. The notice does not disclose expected revenue, profit, margins, or any guidance for the September quarter.

A separate calendar entry had listed an earnings release for Q2 FY27 on November 3, 2026. However, the company’s board-meeting notice specifies November 4, 2026, as the date for considering the results. The official notice is therefore the stated basis for the scheduled results review.

How did Unichem Laboratories perform in Q1 FY27?

Unichem Laboratories reported consolidated revenue of ₹648 crore for the quarter ended June 30, 2026, up 21.52% from the corresponding quarter a year earlier. An earnings summary described the increase as 23% year-on-year, while the quarterly financial summary reported net profit of ₹42 crore, against a net loss of ₹11 crore in June 2025.

Net profit increased 280.73% sequentially from ₹11 crore in the March 2026 quarter, according to the supplied consolidated financial summary. Earnings per share stood at ₹5.89 for June 2026, compared with ₹1.55 in the preceding quarter and a loss per share of ₹1.49 in the year-earlier quarter.

The company’s June 2026 quarterly data also show expenses of ₹563 crore and operating profit of ₹70 crore. Revenue in the March 2026 quarter was ₹599 crore, while revenue in the June 2025 quarter was ₹533 crore. These reported figures provide the immediate base for evaluating the September-quarter disclosure.

What is the financial background before the Q2 FY27 release?

Unichem Laboratories reported revenue of ₹2,202 crore for FY26, up 4.3% from FY25, based on the annual financial data provided. Full-year net income was ₹253 crore, an 84% increase from FY25, and the reported profit margin was 12%, compared with 6.5% in the previous year.

The company’s annual revenue had increased to ₹2,111 crore in FY25 from ₹1,785 crore in FY24. Operating profit in the same annual series was ₹265 crore in FY25, ₹184 crore in FY26, and ₹229 crore on a trailing-12-month basis. The figures indicate that revenue continued to rise over the period, while operating-profit movement differed across the reported periods.

The supplied historical standalone quarterly statement for March 2025 showed net sales turnover of ₹461.24 crore, total income of ₹467.29 crore and reported profit after tax of ₹51.22 crore. That statement should not be directly compared with consolidated figures without accounting for the different reporting basis. The November 4 disclosure is expected to provide both bases for the September 2026 period.

How are investors likely to assess the upcoming results?

Investors will be able to compare Unichem Laboratories’ September-quarter revenue, expenses, operating profit, net profit and EPS with the June-quarter consolidated figures. The Q1 FY27 result established a revenue base of ₹648 crore and a return to profitability, making changes in operating costs and profit conversion relevant areas in the next filing.

The company’s BSE share price closed at ₹483.45 on October 30, 2026, down ₹20.80 or 4.12% for that session. This market movement occurred before the scheduled board meeting and does not establish a direct link with the yet-to-be-approved Q2 financial results.

For the pharmaceuticals sector, quarterly releases are also used to track changes in sales growth, cost levels and earnings per share. But the board-meeting notice itself contains no operational commentary, product updates, demand outlook or capital-allocation announcement. Any assessment of these issues will depend on the results and related disclosures issued after board approval.

Conclusion

The scheduled November 4 board meeting places the focus on Unichem Laboratories’ unaudited Q2 FY27 and first-half performance. Its preceding consolidated quarter reported ₹648 crore in revenue, ₹42 crore in net profit and EPS of ₹5.89, following a loss in the corresponding quarter of the previous year.

The next item to watch is the formal September 2026 filing in consolidated and standalone formats after the board’s consideration. Investors will be able to compare the reported numbers with Q1 FY27 revenue of ₹648 crore, expenses of ₹563 crore and operating profit of ₹70 crore, while also noting any official commentary accompanying the results.